{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:50:53Z","timestamp":1787849453006,"version":"build-2784847793"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The use of cryoablation, a minimally-invasive image-guided technique to target and kill cancer cells, continues to gain traction within the medical field and with patients. This includes the use of cryoablation for the treatment of small breast cancers and focal sites of metastatic disease. In comparison to open surgical approaches, length of hospital stay and recovery time are decreased with the use of cryoablation. Research studies have also found that cryoablation may actually enhance tumor susceptibility to immunotherapy agents. Immunotherapy enhances a person\u2019s own immune system to identify and attack cancer cells. It is proposed that after cryoablation there is increased expression of tumor specific antigens which the body can recognize as foreign invaders and with the combination of immunotherapy, result in an even more robust and efficient attack on the cancer cells. In this review we aim to highlight some of the recent advances in cryoablation which support the potential for cryoablation to induce these tumor-specific immune responses and thus supporting the use of combining cryoablation and immunotherapy for the treatment of breast cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1026475","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:25:20Z","timestamp":1666848320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["An update on the use of cryoablation and immunotherapy for breast cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Akindele","family":"Olagunju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Forsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s197406","article-title":"Cryoablation in the management of breast cancer: Evidence to date","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Breast Cancer: Targets Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2021200134","article-title":"Cryoablation and immunotherapy for breast cancer: Overview and rationale for combined therapy","volume":"3","author":"Regen-Tuero","year":"2021","journal-title":"Radiol: Imaging Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.09.009","article-title":"Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines","volume":"40","author":"Sanchez","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1685300","article-title":"A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer","volume":"9","author":"DeVette","year":"2020","journal-title":"OncoImmunology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00360","article-title":"Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis","volume":"10","author":"Gaudino","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00024","article-title":"Cell type-specific regulation of immunological synapse dynamics by B7 ligand recognition","volume":"7","author":"Brzostek","year":"2016","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1586\/era.12.147","article-title":"Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade","volume":"12","author":"Emens","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"B9","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171708","article-title":"Termination of T cell priming relies on a phase of unresponsiveness promoting disengagement from APCs and T cell division","volume":"215","author":"Bohineust","year":"2018","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5275-3","article-title":"A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: Results from ACOSOG (Alliance) Z1072","volume":"23","author":"Simmons","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00085","article-title":"Immunotherapy plus cryotherapy: Potential augmented abscopal effect for advanced cancers","volume":"8","author":"Abdo","year":"2018","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9251375","DOI":"10.1155\/2016\/9251375","article-title":"Thermal ablative therapies and immune checkpoint modulation: Can locoregional approaches effect a systemic response","volume":"2016","author":"Mehta","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-065X.2011.01006.x","article-title":"Armed response: how dying cells influence T-cell functions","volume":"241","author":"Ferguson","year":"2011","journal-title":"Immunol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11157-w","article-title":"Tumor-infiltrating lymphocytes (TILs) as a biomarker of abscopal effect of cryoablation in breast cancer: A pilot study","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930461","article-title":"Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A pilot study of preoperative single-dose ipilimumab and\/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0013","article-title":"Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy","volume":"4","author":"Page","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell Mol Biol Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1026475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:25:24Z","timestamp":1666848324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1026475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.1026475"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1026475","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"1026475"}}